Unicorn Nest Logo

VC Fonds Technologie Berlin

Total investments

23

Average round size

9M

Portfolio companies

18

Lead investments

1

Follow on index

0.22

Exits

5

Stages of investment
Early Stage Venture
Areas of investment
AutomotiveBiotechnologySoftwareInformation TechnologyHealth CareManufacturingMedicalDigital MarketingTherapeuticsMobile Devices

Investments analytics

Analytics

Total investments
23
Lead investments
1
Exits
5
Follow on index
0.22
Investments by industry
  • Health Care (9)
  • Software (5)
  • Biotechnology (5)
  • Automotive (4)
  • Therapeutics (4)
    • Show 36 more
Investments by region
  • Germany (22)
  • United States (1)
Peak activity year
2017

Discover reliable insights

Leverage validated data, identify key contacts and secure funding opportunities for your business.
Sign Up

Quantitative data

Avg. startup age at the time of investment
11
Avg. valuation at time of investment
2M
Group Appearance index
0.96
Avg. company exit year
8
Avg. multiplicator
0.38

Need more data?

Get access to full data about investors, including their team, contact information, and historic data.

Upgrade

Latest deals

Company name Deal date Industry Deal stage Deal size Location
Data Governance Workshop 13 Dec 2021 Internet, E-Learning, EdTech, Education Early Stage Venture Beijing, Dongcheng District, China
Noxxon Pharma 03 May 2007 Biotechnology, Health Care, Pharmaceutical Late Stage Venture 43M Berlin, Berlin, Germany
Scopis 19 Nov 2013 Health Care, Manufacturing, Augmented Reality, Navigation Early Stage Venture Berlin, Berlin, Germany
How we get our data

At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).

Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.